AbbVie Inc.

Company Overview

AbbVie generates revenue by discovering, developing, manufacturing, and selling innovative pharmaceutical products globally. The company holds a leading market position in immunology with key drugs like Skyrizi and Rinvoq, as well as a strong presence in neuroscience and aesthetics. Its core competitive advantage stems from a robust portfolio of patent-protected, high-growth specialty medicines and a deep research and development pipeline.

Revenue Structure

AbbVie's primary revenue streams are derived from its pharmaceutical products, with immunology drugs accounting for the largest share, followed by neuroscience, oncology, and aesthetics products. Its immunology portfolio, anchored by Skyrizi and Rinvoq, is the largest contributor to revenue, with significant contributions also from its neuroscience and aesthetics franchises.

Key Risks

Key Points

AbbVie presents an attractive investment for its successful navigation of the Humira patent cliff, demonstrating robust growth from its next-generation immunology portfolio and diversified assets. The company's strong free cash flow generation and commitment to a growing dividend further bolster its appeal as a long-term pharmaceutical holding.